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Abstract: This review article aims to provide an introduction to the methodology of health 
economic assessment of a health technology. Attention is paid to defining the fundamental 
concepts and terms that are relevant to health economic assessments. The article describes 
the methodology underlying a cost  study  (identification, measurement and valuation of 
resource use, calculation of costs), an economic evaluation (type of economic evaluation, 
the  cost-effectiveness  plane,  trial-  and  model-based  economic  evaluation,  discounting, 
sensitivity analysis, incremental analysis), and a budget impact analysis. Key references are 
provided  for  those  readers  who  wish  a  more  advanced  understanding  of  health  
economic assessments. 
Keywords: health economics; health technology; cost study; economic evaluation; budget 
impact analysis 
 
 
1. Introduction 
 
Over the past decades, health technologies have made a major contribution to improving the health 
status  of  populations  [1].  At  the  same  time,  during  the  1995–2005  period  the  countries  of  the 
Organization for Economic Co-operation and Development (OECD) have witnessed an annual average 
health expenditure growth per capita of 4%. Growth in health expenditures outpaced the economic 
growth of 2.2% during the same period. Health expenditure growth can be attributed to a number of 
factors,  including  ageing  populations,  the  increasing  prevalence  of  chronic  conditions,  health  care 
resource use price inflation, technological advances, and increased expenditures on drugs. With respect 
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to  the  latter,  annual  average growth  in  pharmaceutical  expenditure  per  capita of 4.6% during the  
1995–2005 period exceeded the annual rise in health expenditures [2]. 
In  response  to  this,  governments  seek instruments  that can aid  the implementation  of safe and 
effective  health  technologies  that  support  further  health  improvements,  whilst  containing  health 
expenditures. Health economic assessment provides a tool to maximize population health subject to 
scarce  resources  [3]  and  to  consider the extent to  which a technology will be used. Furthermore, 
evidence derived from health economic assessments is used to inform decisions about the registration, 
pricing/reimbursement  of  health  technologies  in  an  increasing  number  of  countries  [4].  The 
requirement  for  health  economic  assessment  fits  within  an  overall  trend  towards  evidence-based 
decision making in health care [5]. 
The aim of this article is to provide an introduction to the science underlying the health economic 
assessment of a health technology. This article serves as a resource for readers who want a succinct 
overview of the methodology and use of health economic assessment. Particular attention is paid to 
defining the fundamental concepts and terms that are relevant to health economic assessment. Key 
references are added for those readers who wish a more advanced understanding of these topics.  
 
2. Health Economics (Assessment) 
 
Health economics as a scientific discipline that applies economic principles to health and health  
care [6]. Health economic aspects include, amongst other things, health policy and regulation, the 
organization and financing of health care, international comparisons of health care systems, the supply 
of and demand for health care, inequalities in health, the supply of and demand for health insurance. 
One specific aspect  of health economics involves the assessment of a health technology. Such an 
assessment may consist of a cost study, a budget impact analysis and/or an economic evaluation. This 
article focuses on these three health economic assessment techniques. 
 
3. Cost Study 
 
A cost study can serve multiple purposes. Cost estimates can underline the importance of a disease 
to society when considered alongside its impact on morbidity and mortality and when compared with 
the economic burden of other diseases. Furthermore, cost studies may allow the identification of the 
drivers of diagnosis and treatment costs. Finally, cost data can be fed into economic evaluations, so 
that decision makers can ascertain the efficiency of various approaches to diagnosing and treating a 
disease by examining their consequences in relation to their costs. 
Information about costs can be derived from a cost-of-illness analysis or from a cost analysis. A 
cost-of-illness analysis quantifies the economic burden of a disease to society by measuring the costs of 
diagnosing and treating a disease, as well as the costs arising as a result of the disease (for instance, 
productivity losses due to time taken off work). A cost analysis compares the costs of two or more 
approaches to diagnosis and treatment of a disease (for instance, medical versus surgical therapy). 
The following categories of costs can be distinguished [7]: direct costs refer to the costs of health 
care services such as costs of drugs, physician visits and hospitalisation. If health care services keep a Int. J. Environ. Res. Public Health 2009, 6                 
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patient alive, the patient is likely to fall ill in the future and require additional health care services. 
Health care costs in the added years of life as a result of keeping patients alive may also be counted as 
direct  costs.  Direct  costs  sometimes  include  patients‘  out-of-pocket  expenses such as  the costs of 
transportation  to  the  hospital  and  the  costs  of  child  care  while  the  patient  is  receiving  treatment. 
Indirect costs reflect the costs of productivity loss as a result of the disease. These costs not only 
consist of the productivity loss of the patient, but also of the productivity loss of family or friends who 
take time off work to care for the patient. The productivity loss may take the form of time lost from 
work (‗absenteeism‘) or reduced productivity at work (‗presenteeism‘).  
Costs originate in the health care sector and in other sectors. For instance, treatment of opiate-
dependent drug users involves the health sector (through the provision of maintenance or detoxification 
programmes), but also relies on the input from social care agencies. Furthermore, some studies have 
demonstrated that treatment costs are offset by savings arising from the prevention of future health care 
use and the reduction in criminal justice expenditure [8]. Costs are incurred by the health care payer 
(i.e., insurance funds or national health service), the patient/family (e.g., drug co-payment, costs of 
home adaptation) and by the society at large (e.g., costs of productivity loss).  
Once  the  relevant  resource  use  has  been  identified,  measured  and  valued,  costs  can  be  
calculated [9,10]. These four steps are now described in detail in the following sections. 
 
3.1. Identification of Resource Use 
 
The perspective of the study determines which items of resource use need to be taken into account. 
A cost study can take a societal perspective by considering all (in)direct (non-)health care resource 
uses. Alternatively, the more narrow perspective of a Ministry of Health, health care payer, hospital or 
patient can be adopted. In these instances, the cost study considers those items of resource use that are 
relevant  from  the perspective of the study. For instance, productivity loss as a result of illness is 
included in a cost study from the societal perspective. However, productivity loss is not relevant to the 
Ministry of Health and is, thus, excluded from a study with such a perspective. 
The time horizon of a cost study needs to cover all relevant resource use. This applies to cost 
analyses,  particularly  those  of  immunization  or  vaccination  programmes.  Such  programmes  are 
associated with the use of drugs in the short-term, but may lead to savings from reduced health care 
resource use and from less productivity loss in the future. The time horizon needs to be sufficiently 
long to be able to investigate whether present drug costs are offset by future cost savings. The time 
horizon is also relevant to cost-of-illness analyses. A cost-of-illness analysis may take the form of a 
prevalence-based  study,  which  measures  costs  attributable to  a group of patients  suffering from  a 
disease during a given time interval. For instance, a literature review indicated that cost-of-illness 
analyses of endometriosis measured costs during a time period varying from six months to five years. 
This period was too short to account for the chronic nature of endometriosis which may afflict women 
during their reproductive years [11]. Therefore, cost-of-illness analyses need to take the form of an 
incidence-based study, quantifying costs of a disease from onset to end. 
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3.2. Measurement of Resource Use 
 
Two approaches can be adopted to measure the volume of resource use. On the one hand, a micro-
costing  or  bottom-up  approach  identifies  and  measures  each  relevant  item  of  resource  use.  This 
approach generates estimates of resource use with a high level of precision. However, this approach is 
time-intensive, expensive, and may yield estimates  that are context-specific. On the other hand, a 
gross-costing or top-down approach measures resource use at the aggregate level (e.g., at the level of 
diagnosis-related groups) without specifying individual items. Such estimates benefit from increased 
generalisability and improve comparability of cost studies, but are less precise. 
In  terms  of  data  sources,  resource  use  can  be  measured  in  a  sample  of  patients  (primary  data 
collection). A cost study can follow up patients suffering from a specific disease. Such case series that 
focus on identified patients only may be misleading in the case of diseases where diagnosis is complex 
and attribution of resource use to the disease is difficult. Studies comparing patients with/without a 
disease  are  better  suited  in  that  they  allow  identification  of additional resource use related to  the 
disease. Resource use can also be derived from existing sources such as patient medical records, a 
health care payer claims database, the published literature, other routine data sources or large scale 
secondary datasets (secondary data collection). Patient medical records provide detailed information 
about health care resource use. On the one hand, such data tend to pertain to a specific institution(s), 
thus limiting the generalisability of cost estimates. On the other hand, it may be possible to extract 
medical record data from a representative patient sample or from a sample of patients from multiple 
institutions. An analysis of claims data benefits from comprehensiveness of information on health care 
resource use, but may suffer from missing data and incorrect diagnostic coding of claims. Resource use 
data can be gathered from the literature, although differences in the design of primary studies may 
restrict comparability of estimates. The key issue is that secondary data sources may not fit the question 
that a health economic assessment seeks to address. 
 
3.3. Valuation of Resource Use 
 
The principle of valuing resource use is based on the notion of ‗opportunity cost‘. The opportunity 
cost represents the cost of using resources for some purpose, measured as their value in their next best 
alternative use. In the context of health economic assessment, the valuation of resource use puts a 
monetary  value  on  the  resources  depleted  by  the  disease  and  its  treatment.  Economic  theory 
demonstrates that market prices in a free and perfectly competitive market represent opportunity costs. 
Thus, in order to value resource use, the volume of resource use needs to be multiplied by market 
prices.  However,  market  prices  do  not  always  exist.  For  instance,  drug  prices  may  be  negotiated 
between  the  government  and  the  pharmaceutical  company.  Therefore,  researchers  use  official  list 
prices to calculate charges. Caution needs to be exercised when calculating charges as these do not 
necessarily reflect the worth of resource use. For instance, charges of surgical treatment in hospital may 
not accurately measure actual expenditure on administration, billing, capital depreciation, maintenance, 
laundry and other hospital services related to the surgical procedure.  Int. J. Environ. Res. Public Health 2009, 6                 
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Alternatively, shadow prices can be used to value resource use in the absence of market prices. This 
can be illustrated with the valuation of productivity loss. If the patient is an employee, his/her wage can 
be used to value lost productivity. If the patient is a housewife, this approach cannot be used as a 
housewife does not receive a wage. Instead, researchers need to draw on a shadow price, i.e., the 
market price of a similar activity. In this example, the market wage of a professional housekeeper 
could serve as the shadow price and could be used to value the productivity loss of the housewife. 
 
3.4. Calculation of Costs 
 
When calculating the costs of a health care programme, the question arises of whether to compute 
marginal or average costs. Dividing total costs by the number of units generates average costs. Average 
costs include fixed costs (e.g., costs of hospital infrastructure) as well as variable costs. Marginal costs 
represent the costs of producing one additional unit and, therefore, include variable costs only. As our 
interest is in the additional costs incurred by the health care programme, a cost study needs to calculate 
marginal costs. However, the distinction between average and marginal costs is not always clear. If the 
national  implementation  of a health care programme involves  building a new hospital, the use of 
average  costs  is  recommended  as  they  measure  the  fixed  costs  of  the  hospital  infrastructure. 
Alternatively, these hospital costs can be viewed as marginal costs as they represent the additional 
costs imposed by the programme. 
 
4. Economic Evaluation 
 
An economic evaluation is in essence a comparative analysis of at least two health technologies in 
terms of both their costs and consequences [7]. Figure 1 portrays the components of an economic 
evaluation of a new drug therapy vis-à -vis a comparator. The comparator is generally chosen to reflect 
common clinical practice in the setting where the economic evaluation is undertaken. In our example 
of a new drug therapy, the comparator can be an older drug or another health technology. If the new 
drug represents the first technology that is available to treat a specific disease, the relevant comparator 
may be no active therapy. 
Figure 1. Components of an economic evaluation. 
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An  economic  evaluation  enables  us  to  answer  efficiency  questions  by  relating  the  costs  to  the 
consequences of alternative health technologies. An incremental analysis is carried out to express the 
results  of  an  economic  evaluation.  This  means  that,  for  meaningful  comparison,  an  economic 
evaluation expresses the additional costs incurred by one health technology vis-à -vis the comparator in 
relation to the additional consequences of that technology vis-à -vis the comparator.  
 
4.1. Types of Economic Evaluation 
 
An economic evaluation can take a number of forms. A cost-minimisation analysis is appropriate 
when  the  alternative  health  technologies  produce  equivalent  consequences.  In  this  case,  a  
cost-minimisation  analysis  identifies  the  least  costly health technology. For instance, an economic 
evaluation  examined  the  efficiency  of  two  antibiotics  (teicoplanin  and  vancomycin)  used  in  the 
treatment of intensive care unit patients with catheter-related infections [12]. Comparative trials of 
teicoplanin  and  vancomycin  reported  no  significant  differences  in  their  consequences  (i.e., 
effectiveness and safety). Therefore, a cost-minimisation analysis compared costs of drug acquisition, 
materials required for preparation and administration of antibiotics, laboratory tests and nursing time. 
Treatment with teicoplanin turned out to be more expensive than vancomycin. This was because lower 
costs of laboratory tests with teicoplanin only partially offset higher drug acquisition costs. 
A cost-effectiveness analysis denotes an economic evaluation that measures costs in a monetary unit 
and quantifies a single consequence in a physical or natural unit (e.g., the number of successfully 
treated  patients,  the  number  of  life  years  gained,  the  number  of  symptom  days  averted).  Final 
consequence measures (e.g., life years gained) are preferred to intermediate measures (e.g., cholesterol 
level) as our interest is in the ultimate impact of a technology on health. Also, as final consequence 
measures are relevant to multiple health technologies and diseases, their use facilitates comparison of 
the efficiency of various technologies. The results of a cost-effectiveness analysis are expressed by 
means of an incremental cost-effectiveness ratio: 
Incremental cost-effectiveness ratio = (C1 − C0) / (E1 − E0) 
where C1 is the cost of the health technology; C0 is the cost of the comparator technology; E1 and E0 
are the consequences of the technology and the comparator, respectively. 
A  cost-effectiveness  analysis  is  only  possible  if  the  health  technologies  affect  the  same 
consequence.  However,  technologies  may  affect  multiple  consequences.  In  this  case,  a  
cost-consequence analysis can be carried out, which presents costs and multiple consequences. One use 
of a cost-consequence analysis is to highlight the choices and trade-offs that exist between different 
consequences. The drawback is that a cost-consequence analysis does not provide an assessment of the 
overall efficiency of a health technology.  
The  previous  types  of  economic  evaluation  pose  a  number  of  challenges.  In  particular,  health 
technologies  may  impact  multiple  consequences,  consequences  may  differ  between  health 
technologies, and patients may attach more importance to some consequences than others. In response 
to this, the two following types of economic evaluation have been developed that combine and value 
the various consequences in a single generic measure of health improvement. Int. J. Environ. Res. Public Health 2009, 6                 
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An economic evaluation that measures costs and consequences by means of specific health-related 
quality of life measures, such as quality-adjusted life years, is referred to as a cost-utility analysis. The 
quality-adjusted  life  year  takes  into  account  the  quantity  and  quality  of  life.  The  quality  of  life 
associated with a health state is measured through the use of health utilities. A utility reflects the 
preference of an individual for the health state. Utilities are elicited on a scale of 0 (reflecting death) to 
1 (reflecting perfect health) using techniques such as the visual analogue scale, the standard gamble or 
the time trade-off [13]. Quality of life data are then combined with estimates of the time period for 
which  the  health  benefits  last  to  generate  quality-adjusted  life  years.  The  results  of  a  cost-utility 
analysis using quality-adjusted life years are expressed by means of an incremental cost-utility ratio: 
Incremental cost-utility ratio = (C1 − C0) / (Q1 − Q0) 
where C1 is the cost of the health technology; C0 is the cost of the comparator technology; Q1 and Q0 
are  the  number  of  quality-adjusted  life  years  associated  with  the  technology  and  the  
comparator, respectively. 
A cost-benefit analysis values consequences in monetary terms (the ‗benefits‘) in addition to costs. 
A monetary value can be assigned to  consequences by means of the human capital approach, the 
revealed preference approach or the willingness-to-pay technique [14]. However, assigning monetary 
values to consequences is controversial and further work on methods to value consequences needs to 
be carried out. As both costs and consequences are expressed in monetary terms, costs can be directly 
compared  with  benefits  and  the  net  worth  (benefits  minus  costs)  of  a  health  technology  can  be 
estimated. The results of a cost-benefit analysis may be stated in the form of the net benefit (or net 
loss) of one health technology over another or in the form of an incremental cost-benefit ratio:  
Net benefit = (B1 − B0) - (C1 − C0) 
Incremental cost-benefit ratio = (C1 − C0) / (B1 − B0) 
where C1 is the cost of the health technology; C0 is the cost of the comparator technology; B1 and B0 
are the benefits of the technology and the comparator, respectively. 
 
4.2. The Cost-Effectiveness Plane 
 
The  question  whether  to  conduct  an  economic  evaluation  can  be  answered  by  looking  at  the  
so-called  cost-effectiveness  plane  (see  Figure  2)  [15].  On  the  horizontal  axis,  the  difference  in 
effectiveness (e.g., life years) between the health technology and the comparator is portrayed. The 
vertical axis represents the cost difference between the technology and the comparator. The technology 
may have higher or lower costs, and higher or lower effectiveness than the comparator, so that its point 
may fall into one of the four quadrants. 
If  the  point  falls  into  quadrant  2,  the  technology  is  more  effective  and  less  costly  than  the 
comparator.  In  other  words,  the  technology  dominates  the  comparator.  This  indicates  that  the 
technology  needs  to  be  adopted  and  that  there  is  no  need  to  conduct  an  economic  evaluation. 
Conversely,  if  the  point  falls  into  quadrant  4,  the  comparator  dominates  the  technology  and  the 
comparator should be adopted. In quadrants 1 and 3, one option is more effective, but also more costly 
than the other option. In these cases, an economic evaluation needs to be carried out. Authorities in Int. J. Environ. Res. Public Health 2009, 6                 
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some  countries  have  specified  cost-effectiveness  thresholds,  which  serve  to  determine  whether  a 
technology is efficient or not (cfr. infra). Such a threshold represents the maximum cost per life-year 
gained that authorities are willing to pay for a health technology. The gradient of the dashed line 
represents  one  cost-effectiveness  threshold.  The  technology  is  efficient  if  its  point  falls  to  the  
south-east of this dashed line. 
Figure 2. The cost-effectiveness plane. 
 
 
What is the empirical evidence of the value of health technologies? A recent study reviewed 599 
articles providing data on 1,500 cost-effectiveness ratios of health technologies [16]. Technologies 
included preventive measures (interventions designed to avert disease or injury) and curative measures 
(interventions  designed  to  reverse or retard progression  of an existing condition  and interventions 
designed to ameliorate the effects of a disease). The distribution of preventive measures spanned the 
full range of cost-effectiveness results: preventive measures included dominant measures, measures 
with  a  positive  incremental  cost-effectiveness  ratio  and  dominated  measures.  In  fact,  preventive 
measures and curative measures exhibited a similar distribution of cost-effectiveness ratios. 
 
4.3. Trial- and Model-Based Economic Evaluation 
 
There are two ways to carry out an economic evaluation: a trial-based economic evaluation or a 
model-based economic evaluation [17]. 
An economic evaluation can be carried out alongside a clinical trial. Such evaluations are called 
trial-based economic evaluations or piggy-back studies. In the case of a piggy-back study of a new 
drug, the economic evaluation can be carried out alongside a Phase III clinical trial, which examines 
the efficacy and adverse reactions during the drug development process. Such economic evaluations 
provide  timely  information  with  high  internal  validity  that  can  be  used  by  manufacturers,  policy Int. J. Environ. Res. Public Health 2009, 6                 
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makers,  healthcare  professionals  and  patients  to  assess  the  value  of  a  new  drug.  The  economic 
evaluation  can  also  be  conducted  alongside  a  Phase  IV  clinical  trial,  which  examines  long-term 
effectiveness  following  regulatory  approval  of  the  drug.  Such  economic  evaluations  explore  the 
efficiency  of  a  new  drug  under  conditions  of  day-to-day  practice  and  benefit  from  greater  
external validity. 
There is a wide diversity in the design, conduct and analysis of trial-based economic evaluations. 
However,  a  number  of  good  research  practices  have  emerged  [18].  A  gold  standard  trial-based 
economic evaluation should have adequate power with a view to testing hypotheses about expected 
differences in costs and consequences. An adequate time horizon needs to capture the long-term impact 
of the health technology. The choice of consequence measures in the trial must be suited for use in the 
economic evaluation. For instance, quality-of-life values derived from the trial can be used to calculate 
quality-adjusted life years in a cost-utility analysis. The identification, collection and management of 
economic  data  should  be  fully  integrated  into  the  clinical  trial.  Data  analysis  should  follow  an 
intention-to-treat  approach,  assess  uncertainty,  take  account  of  time  preference  for  costs  and 
consequences, and account for missing or censored data. Appropriate summary measures need to be 
used to calculate the relative value of the technology vis-à -vis the comparator.  
Nevertheless, there are some drawbacks to using piggy-back studies for the purpose of economic 
evaluation. These include: 
  Inadequate sample size; 
  Restrictive patient selection (patient characteristics, co-morbidities, disease severity); 
  Inappropriate comparator; 
  Short time horizon; 
  Occurrence of protocol-driven resource use (which leads to over-estimation of costs); 
  Artificially enhanced compliance; 
  Inappropriate consequence measures; 
It  needs  to  be  emphasised  that  trials  are  conducted  for  a  wide  variety  of  purposes  (e.g.,  dose 
response, safety, efficacy, effectiveness) and as such may or may not be suitable for consideration of 
cost-effectiveness as an economic evaluation considers whether an intervention is worth adopting into 
practice. As a consequence some or all of the drawbacks may exist. They are less likely to exist in a 
study that is explicitly designed to address cost-effectiveness as a primary outcome. 
Even if a trial-based economic evaluation exists and is suitable, some form of modeling is likely to 
be needed. For instance, to examine the full impact of a health technology, statistical modeling beyond 
the time horizon of the trial may be required for the purpose of extrapolation. Also, decision-analytic 
modeling may be used to address some shortcomings of trial-based economic evaluations by allowing 
us to compare all relevant options; to incorporate all appropriate evidence; to translate intermediate 
endpoints into final consequences; to extrapolate over the appropriate time horizon of the evaluation; 
and  to  generalize  to  other  settings  or  populations  [19].  Decision-analytic  modeling  is  the  main 
modeling approach used in health economic assessment and is, in essence, a quantitative approach to 
decision making under conditions of uncertainty. A model can be defined as an analytic methodology 
that accounts for events over time with a view to estimating the impact of a health technology on costs 
and consequences [20]. Decision-analytic modeling can take the form of a decision tree or a Markov Int. J. Environ. Res. Public Health 2009, 6                 
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model. A decision tree is a graphic representation of the various diagnosis and treatment pathways of a 
specific disease in combination with the probabilities, costs and consequences associated with each 
pathway.  A  Markov  model  structures  a  disease  and  its  treatment  process  by  means  of  mutually 
exclusive and exhaustive health states, with patients moving from one health state to another based on 
transition probabilities. The time spent in a health state generates costs and consequences. Estimates of 
probabilities, costs and consequences used in decision trees and Markov models are usually derived 
from the literature or from expert opinion.  
With respect to modeling, concerns have been raised about the inappropriate use of clinical data, 
about biases in observational data, about the difficulties of extrapolation, and about the transparency or 
validity of models [19]. Therefore, it is important to adhere to principles of good practice for modeling 
in economic evaluation by ensuring that the model represents the key features of the decision to be 
made; by presenting the results in a transparent way; by respecting the quality of the data used in the 
model;  and  by  exploring  uncertainty.  Attention  also  needs  to  be  paid  to  validating  the  model  by 
comparing the results with those of similar studies. Finally, the reader should note that a model is only 
as  good  (or  bad)  as  the  quality  of  its  data  and  its  specification.  Thus,  model-based  economic 
evaluations need to clearly state the caveat that the results are conditional on the data and assumptions 
incorporated in the model.  
 
4.4. Discounting 
 
The costs and consequences of a health technology generally do not take place in the same year, but 
may be spread out over multiple years. For instance, current costs of a vaccination programme need to 
be  compared  by  future  benefits  of  prevented  disease  and  reduced  healthcare  costs.  An  economic 
evaluation needs to take account of the timing of costs and consequences because individuals have a 
positive rate of time preference. This means that individuals attach greater importance to current than 
to  future costs and consequences.  This  positive rate of time preference mainly derives from three 
reasons: (a) individuals consider the short run only; (b) individuals are uncertain about the future; and 
(c) individuals can invest a Euro now and expect to receive more than a Euro in the future. Time 
preference is taken into account in an economic evaluation by the process of discounting. Discounting 
calculates the present value of costs and consequences occurring in the future [21]. By calculating 
present values, alternative health technologies with differential timing of costs and consequences can 
be compared from the same baseline.  
 
4.5. Sensitivity Analysis 
 
Any variable used in an economic evaluation is subject to some uncertainty [22]. This uncertainty 
can originate from methodological disagreements, researchers‘ assumptions in the absence of data, 
imprecise data, need to extrapolate results over time, and the need to generalize results to other settings 
or other countries. A sensitivity analysis determines the direction and the extent to which the results of 
the economic evaluation vary when estimates of input variables change.  Int. J. Environ. Res. Public Health 2009, 6                 
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There  are  two  approaches  to  carrying  out  a  sensitivity  analysis  in  a  model-based  economic 
evaluation: deterministic and probabilistic sensitivity analysis. 
A deterministic sensitivity analysis explores the impact on results of changes in one input variable 
(one-way  analysis)  or  of  simultaneous  changes  in  multiple  variables  (multi-way  analysis).  One 
application of a multi-way analysis is a scenario analysis. Such an analysis typically includes a best 
case scenario, where all input variables are changed in the most optimistic way, and a worst  case 
scenario,  where  input  variables  take  on  the  most  pessimistic  values. A scenario analysis provides 
insight into the efficiency of the health technology in the best case and in the worst case. Such an 
analysis may also serve to test the impact of various scenarios on cost-effectiveness results. Finally, a 
threshold analysis identifies the combination of variable estimates that ensures that the incremental 
cost-effectiveness  or  cost-utility  ratio  of  the  technology  does  not  exceed  the  threshold  adopted  
by authorities. 
A probabilistic sensitivity analysis is based on a Monte Carlo simulation. The principle is to run the 
analysis a large number of times (e.g., 10,000 times) with different sets of variable estimates drawn 
from distributions. This requires that a probability distribution is assigned to each input variable. For 
each iteration, the simulation draws input parameters at random from their statistical distributions and 
calculates  cost  and  effectiveness  pairs.  At  the  end  of  the  10,000  iterations,  the  joint  statistical 
distribution for costs and effectiveness is represented as a cloud of points on the cost-effectiveness 
plane (see Figure 2).  
The gradient of the dashed line in Figure 2 indicates one cost-effectiveness threshold. Typically, this 
line cuts through the cloud of cost and effectiveness pairs generated by the probabilistic sensitivity 
analysis. Simulations falling to the south-east of the line support the cost-effectiveness of the health 
technology. The probability that the technology is cost-effective is estimated as the proportion of points 
to the south-east of this line. As the cost-effectiveness threshold increases, the dashed line rotates  
anti-clockwise around the origin, increasing the proportion of points to the right of the line. This allows 
us  to  draw  cost-effectiveness  acceptability  curves  representing  the  probability  that  the  health 
technology is efficient for a range of cost-effectiveness thresholds (see Figure 3) [23].  
Figure 3. Cost-effectiveness acceptability curve. 
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A trial-based economic evaluation of patient-level data is inherently stochastic [22]. To account for 
uncertainty,  confidence  intervals  for  cost-effectiveness  ratios  can  be  estimated  when  the  health 
technology is more effective and less costly than the comparator (quadrant 1 of the cost-effectiveness 
plane, see Figure 2). Multiple methods exist to estimate confidence intervals including the confidence 
box,  Taylor  series  expansion,  confidence  ellipse,  angular  transformation,  Fieller‘s  method  and 
bootstrapping. When uncertainty covers more than one quadrant of the cost-effectiveness plane, a more 
general approach involves the calculation of net benefits, i.e., the additional costs of a technology  
vis-à -vis the comparator divided by a specific cost-effectiveness threshold value. This can be followed 
by the presentation of results in a cost-effectiveness acceptability curve. 
 
4.6. Use of Economic Evaluation by Decision Makers 
 
The  use  of  economic  evaluation  is  corroborated,  for  instance,  by  the  dramatic  increase  in  the 
number of published economic evaluations of health technologies in the last decades. For instance, the 
Tufts Cost-Effectiveness Analysis Registry, which includes more than 1,700 cost-utility analyses of 
health technologies published from 1976 to 2007, shows that the number of cost-utility analyses has 
risen exponentially over time (see Figure 4). Also, specific databases have been developed that contain 
information about economic evaluations of health technologies (e.g., the Health Economic Evaluations 
Database at McMaster University, Hamilton, ON, Canada) [24] and about the methodological quality 
of such economic evaluations (e.g., the National Health Service Economic Evaluation Database at the 
University of York, UK) [25]. 
Figure 4. Trend in cost-utility analyses of health technologies, 1976–2007. 
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As decision makers appreciate the need to evaluate projects in terms of costs and benefits, economic 
evaluation offers a framework that presents information about  health technologies in a format that is 
familiar and useful to them. Economic evaluation may serve as an instrument to demonstrate the value 
of  a  health  technology  with  a  view  to  informing  pricing/reimbursement  decisions  [26].  For  this Int. J. Environ. Res. Public Health 2009, 6                 
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purpose, the results of a cost-effectiveness analysis or cost-utility analysis of a health technology may 
be compared with the cost-effectiveness threshold or cost-utility threshold, respectively, adopted by 
authorities.  Health  technologies  with  a  cost-effectiveness/cost-utility  ratio  below  the  threshold  are 
rewarded by means of a more favourable price/reimbursement. 
Cost-effectiveness and cost-utility thresholds have either been explicitly specified by authorities or 
can be implicitly determined from examining past pricing/reimbursement decisions. Table 1 provides 
an overview of threshold values used to inform pricing/reimbursement decisions in Australia [27], 
Canada [28], England and Wales [29,30], The Netherlands [31], New Zealand [32], and the United 
States [33]. This Table shows that threshold values vary substantially between countries. 
Table 1. Cost-effectiveness/cost-utility threshold values. 
Country  Threshold value in local currency  Threshold value in Euro 
Australia  AUS$42,000–76,000 per life year  24,700–44,700 € per life year 
Canada  CAN$20,000–100,000 per QALY  12,700–63,300 € per QALY 
England and 
Wales 
£ 20,000–30,000 per QALY  22,800–34,100 € per QALY 
Netherlands  20,000–80,000 € per QALY  20,000–80,000 € per QALY 
New Zealand  NZ3,000–15,000 per QALY  1,400–7,200 € per QALY 
United States  US$50,000 per QALY  34,400 € per QALY 
Notes: 
- QALY = quality-adjusted life year. 
- Local threshold values were converted into Euro using market exchange rates on 14th 
September 2009 
 
For instance, the National Institute for Health and Clinical Excellence (NICE) in England and Wales 
uses a threshold value of £ 20,000 per quality-adjusted life year, although health technologies with a 
cost-utility ratio above this threshold can be recommended for use in the National Health Service if 
there is a strong case to do so. A review of NICE guidance issued between 1999 and 2005 concluded 
that  health  technologies  having  a  ratio  exceeding  £ 30,000  per  QALY  were  unlikely  to  be  
recommended [29]. Judgements about what is regarded as an (un)acceptable cost-utility ratio are made 
by  NICE's  advisory  committees,  which  consist  of  clinicians  and  health  managers  working  in  the 
National Health Service, statisticians, health economists, and patients [30]. However, there is a debate 
about whether the use of thresholds is informative, and alternative approaches to assess the value of a 
health technology have been proposed, such as  the replacement approach, program  budgeting and 
marginal analysis, generalized optimization framework, and multi-criteria decision analysis [34]. 
It should be noted that certain aspects of the decision making process restrict the use of economic 
evaluations of health technologies. A first aspect relates to institutional features of the health care 
system.  For  instance,  in  most  European  countries,  health  expenditures  are  divided  across  several 
budgets,  with  a  tendency  for decision makers to  adopt  a silo mentality. This  means  that decision 
makers consider each budget separately, but do not take account of the full impact of a technology 
across  budgets.  This  silo  mentality  poses  challenges  for  economic  evaluation  because  health 
technologies are likely to have an impact on multiple budgets. For instance, although the introduction 
of a new drug may add to the pharmaceutical budget, this may be accompanied by reduced expenditure Int. J. Environ. Res. Public Health 2009, 6                 
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on other health services utilization. Therefore, there is a need to overcome this silo mentality in order 
to enhance the value of economic evaluation. 
Economic evaluations need to report findings that have practical relevance to decision makers. For 
instance, savings arising from fewer hospitalizations are accounted for as a financial benefit in an 
economic evaluation. However, the benefit does not necessarily materialize in a real setting as vacated 
beds may be used in the treatment of other patients. If this is the case, researchers are essentially taking 
into account freed resources, whereas decision makers have an interest in actual financial savings. It is 
therefore important for researchers to understand the perspective of decision makers, to ascertain for 
what purpose decision makers wish to use the information derived from the economic evaluation, and 
to present the results accordingly. 
Although  decision  makers  embrace  the  principle  of  weighing  costs  and  benefits  in  making 
decisions, their actual knowledge of economic evaluation techniques is generally limited and they tend 
to have doubts about the methodological quality of studies [35]. To overcome this barrier, there is a 
need  for  better  education  and  training  of  decision  makers  in  economic  evaluation  techniques. 
Moreover, a higher degree of standardization and consensus surrounding methodological principles of 
economic evaluation is required. 
 
5. Budget Impact Analysis 
 
In addition to information about the efficiency of a new health technology, regulatory agencies in an 
increasing number of countries now require data about the budgetary impact of the technology on 
national, regional or local budgets [36]. Whereas an economic evaluation allows decision makers to 
assess the efficiency of a health technology, a budget impact analysis examines the financial impact of 
the adoption and diffusion of the technology within a particular setting. Thus, a budget impact analysis 
considers  the  affordability  of a technology. Specifically, a budget  impact  analysis explores  how a 
change in the current mix of treatment strategies by the introduction of a new technology will impact 
spending on a disease.  
Budget impact analysis in combination with cost study and economic evaluation play a crucial part 
in  the  comprehensive  assessment  of  a  health  technology  and  may  inform  reimbursement  
decisions [26]. Reimbursement may be withheld from a cost-effective health technology if it has a high 
budgetary  impact.  Conversely,  a  cost-ineffective  technology  may  receive  reimbursement  if  its 
budgetary impact is limited. This is because the opportunity cost of adopting such a technology is low 
(little other activity would need to be displaced) and the adoption may meet other important objectives 
of a decision-maker such as  equity. The reimbursement of orphan drugs,  for instance, shows that 
decision  makers  may  attach  more  importance  to  budget  impact  and  equity  considerations  than  to 
efficiency [37]. 
The methodology of budget impact analysis is still developing, although principles of good practice 
for budget impact analysis have recently been proposed [36]. A budget impact analysis starts with 
providing all relevant epidemiological, clinical and economic information of the disease. Then, the 
current mix of treatment strategies is described. This may cover no active therapy as well as therapies 
that may or may not be replaced by the new health technology. The introduction of the technology may Int. J. Environ. Res. Public Health 2009, 6                 
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lead to technology substitution and market expansion. Therefore, a budget impact analysis considers all 
patients who might be treated with the new technology, including previously untreated patients who 
may now seek treatment. Finally, the analysis considers the budgetary impact of various scenarios of 
how the current mix of treatment strategies changes when the new technology becomes available. 
 
6. Conclusions 
 
Health economic assessment in the form of a cost study, economic evaluation and budget impact 
analysis provides a tool to evaluate health technologies. Indeed, these instruments present information 
about  the  costs,  efficiency  and  affordability  of  a  technology  to  decision  makers  with  a  view  to 
optimising health policy. In order to fully exploit the value of health economic assessment, researchers 
need  to  take  care  to  conduct  such  exercises  according  to  methodologically  sound  principles. 
Additionally, researchers need to take into account the decision making context by identifying the 
various goals that decision makers pursue and by discuss how decision makers can use the findings of 
health economic evaluation to attain these objectives. 
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